Description

Sermorelin Peptide – Research Use Only | Cloud Pharmacy

Overview

Sermorelin is a synthetically engineered 29-amino acid peptide designed to replicate the biological activity of Growth Hormone-Releasing Hormone (GHRH). It represents the shortest active fragment of GHRH (1-29 amide) capable of stimulating the pituitary gland to secrete human growth hormone (hGH). Through this mimicry, Sermorelin has been widely studied in growth hormone deficiency, endocrine regulation, metabolic, and anabolic research models.

Developed in the early 1980s, Sermorelin was among the first peptides identified to effectively induce pulsatile GH secretion. Initial studies in animal models revealed that exogenous administration of GHRH (1-29) amide could activate the pituitary, enhancing growth and metabolic activity. These findings positioned Sermorelin as a foundational compound in peptide endocrinology research.

Scientific Background

Sermorelin comprises the first 29 amino acids of the natural 44-amino acid GHRH structure, yet retains full functional capability at GHRH receptor sites within the pituitary gland. This interaction triggers the release of GH into circulation, which in turn promotes hepatic and peripheral synthesis of Insulin-like Growth Factor-1 (IGF-1) — the principal mediator of growth hormone’s anabolic and metabolic effects.

The peptide’s half-life averages 11–12 minutes, ensuring transient yet potent receptor engagement. Its receptor selectivity allows for targeted GH stimulation without significantly altering other hormones such as insulin, cortisol, thyroid hormones, glucose, or prolactin. This receptor specificity makes Sermorelin a valuable subject for precision endocrine research.

Chemical Composition

Molecular Formula: C₁₄₉H₂₄₆N₄₄O₄₂S
Molecular Weight: 3357.93 g/mol
Chemical Name: GRF (1-29) amide
Synonyms: Sermorelin acetate, GHRH (1-29)
Classification: Growth Hormone-Releasing Hormone Analog

Mechanism of Action

Sermorelin is believed to interact directly with GHRH receptors on pituitary somatotroph cells, initiating a cascade of intracellular signaling events. Upon binding, Sermorelin likely activates adenylate cyclase, which converts ATP into cyclic adenosine monophosphate (cAMP). The resulting rise in cAMP activates Protein Kinase A (PKA), which phosphorylates downstream target proteins and promotes GH exocytosis.

Through this mechanism, Sermorelin induces endogenous GH release while preserving natural feedback control mechanisms. Elevated GH levels subsequently stimulate IGF-1 synthesis, leading to potential anabolic, metabolic, and reparative effects at the cellular level.

Research Findings

1. Sermorelin and GHRH Receptors

Molecular studies indicate that Sermorelin’s binding to GHRH receptors may structurally activate receptor domains responsible for GH secretion. The activation of the cAMP-PKA signaling pathway has been shown to result in the pulsatile release of growth hormone, similar to physiological secretion patterns observed in normal endocrine function. (12)

2. Sermorelin and Growth Velocity

In animal models of idiopathic growth hormone deficiency, researchers observed that continuous administration of Sermorelin was associated with increased growth velocity and skeletal development. The effect persisted for up to 36 months, suggesting sustained pituitary responsiveness with prolonged presence of the peptide. (7)

3. Anabolic and Metabolic Outcomes

In controlled laboratory settings, Sermorelin has been reported to enhance average GH levels by 82–107%, while raising IGF-1 by approximately 28%. Over a 16-week study period, researchers noted an increase in lean body mass (1.26 kg or 2.78 lbs), and significant improvements in skin thickness and tissue density, indicative of an anabolic response driven by elevated GH and IGF-1 levels. (13,14)

4. Lipodystrophy and Body Composition

In a 12-week, double-blind study of HIV-positive subjects with lipodystrophy, Sermorelin administration was associated with a significant increase in IGF-1 and lean body mass, alongside a decrease in visceral adiposity and trunk-to-limb fat ratio. No adverse impact was observed on glucose or insulin regulation. (8)

5. Cognitive and Neurological Research

Clinical research on adults aged 68–69 demonstrated that Sermorelin administration correlated with improved performance on the Wechsler Adult Intelligence Scale (WAIS) — specifically in verbal, picture arrangement, and problem-solving domains. Researchers propose that GH and IGF-1 upregulation may enhance neural plasticity and cognitive efficiency. (9)

6. Oncological Research

A large-scale screening of 1,018 glioma patients across more than 4,000 compound exposures revealed that Sermorelin induced notable tumor cell sensitivity. The peptide appeared to interfere with glioma cell cycle progression, suggesting potential anti-proliferative activity warranting further study. (10)

7. Hypogonadism and Endocrine Modulation

In studies involving both young and elderly male models, Sermorelin was observed to stimulate FSH and LH release, potentially influencing testosterone production. While increases in testosterone were modest and not statistically significant, GH peaks were observed predominantly during nocturnal cycles, suggesting potential normalization of circadian endocrine rhythms. (11)

Potential Research Applications

Sermorelin continues to be a focus of diverse experimental research, including:

Growth hormone deficiency and pituitary regulation
Muscle and tissue regeneration studies
Lipodystrophy and body composition analysis
Cognitive aging and neuroplasticity
Hormonal balance and endocrine modulation
Tumor biology and cellular proliferation models

Storage and Handling

Form: Lyophilized peptide powder
Purity: ≥ 98% (HPLC Verified)
Storage: -20°C (long-term); 2–8°C (short-term)
Reconstitution: Sterile water for laboratory use only

Disclaimer

Sermorelin peptide is supplied by Cloud Pharmacy for research and laboratory use only. It is not approved for human consumption, medical treatment, or veterinary use. All research must comply with applicable regulations and institutional safety protocols. Please review our Terms and Conditions before ordering.

References

Garcia JM, Merriam GR, Kargi AY. Growth Hormone in Aging. [Updated 2019 Oct 7]. In: Feingold KR, Anawalt B, Boyce A, et al. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Link
Prakash, A, and K L Goa. “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.” BioDrugs vol. 12,2 (1999): 139-57. PubMed
National Center for Biotechnology Information. “PubChem Compound Summary for CID 16129620, Sermorelin” PubChem
Clark, R G, and I C Robinson. “Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats.” Nature vol. 314,6008 (1985): 281-3. PubMed
Drugs at FDA: FDA Approved Drugs. FDA Database
Junichi I. et al, Growth hormone secretagogues: history, mechanism of action, and clinical development, JSCM Rapid Communications Vol. 3 Issue 1, 09 February 2020. DOI
Prakash, A, and K L Goa. “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.” BioDrugs (1999). PubMed
Koutkia, Polyxeni et al. “Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.” JAMA vol. 292,2 (2004): 210-8. PubMed
Vitiello, Michael V et al. “Growth hormone releasing hormone improves the cognition of healthy older adults.” Neurobiology of Aging vol. 27,2 (2006): 318-23. PubMed
Chang, Yuanhao et al. “A potentially effective drug for patients with recurrent glioma: sermorelin.” Annals of Translational Medicine vol. 9,5 (2021): 406. PMC
Sinha, Deepankar K et al. “Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.” Translational Andrology and Urology vol. 9,Suppl 2 (2020): S149-S159. PMC
Zhou, F. et al. “Structural basis for activation of the growth hormone-releasing hormone receptor.” Nature Communications, 11(1), 5205 (2020). DOI
Vittone, J. et al. “Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.” Metabolism: Clinical and Experimental, 46(1), 89–96 (1997). DOI
Khorram, O., Laughlin, G. A., & Yen, S. S. (1997). “Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.” The Journal of Clinical Endocrinology and Metabolism, 82(5), 1472–1479. DOI

Reviews

There are no reviews yet.

Be the first to review “Sermorelin (5mg)”

Quantity	Discount	Price
5 – 8	5%	$45.60
9 +	10%	$43.20

Sermorelin (5mg)